Xenotransplantation
Executive Summary
Unanimous approval given by the Biological Response Modifiers Advisory Committee July 30 to a report issued by the Xenotransplantation Subcommittee following its Dec. 7 meeting. At issue was the subcommittee's recommendation that FDA should allow xenotransplant clinical trials; FDA's decision to issue a guidance, due in late 1998, that may streamline clinical trials by establishing requirements for biological assays; the establishment of an electronic registry that would track recipients from transplant to death and also track donor sources; the establishment of a national xenotransplantation advisory committee to keep the public informed; and the committee's desire for worldwide harmonization of regulations governing xenotransplantation
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: